Ad
BPMC - Blueprint Medicines Corporation Stock Trading
About | Blueprint Medicines Corporation (NASDAQ:BPMC)
Not available
Quote | Blueprint Medicines Corporation (NASDAQ:BPMC)
| Last: | $49.93 |
|---|---|
| Change Percent: | -0.56% |
| Open: | $50.21 |
| Close: | $49.93 |
| High: | $50.54 |
| Low: | $48.26 |
| Volume: | 437,495 |
| Last Trade Date Time: | 09/27/2023 03:00:00 am |
News | Blueprint Medicines Corporation (NASDAQ:BPMC)
-
2023-08-03 12:51:01 ET Summary Blueprint Medicines reported Q2 earnings with revenue of $57.6M (+57.6% Y/Y) but a net loss of $132.8M. The company unveiled a "precision at scale" growth strategy, targeting a $1.5 billion market, while emphasizing financial discipline and innovatio...
-
2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...
Message Board Posts | Blueprint Medicines Corporation (NASDAQ:BPMC)
| Subject | By | Source | When |
|---|---|---|---|
| Why the drop today...the news release seems positive...anyone | ziggy7796 | investorshub | 08/17/2022 2:40:48 PM |
| BPMC buy 98.69 | stocktrademan | investorshub | 09/12/2021 4:19:19 AM |
| Blueprint Medicines Corp. | TFMG | investorshub | 06/21/2020 6:15:20 PM |
| Avapritinib Today is the date | Frankestin | investorshub | 05/14/2020 10:35:40 AM |
| Sold near EOD @ $59.60. Earnings pre-market tomorrow. | chmcnfunds | investorshub | 07/31/2018 7:58:12 PM |
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Ad
-
2023-08-02 13:00:51 ET Shares of Blueprint Medicines (NASDAQ: BPMC) were down more than 12% as of 12:45 p.m. on Wednesday after the healthcare company announced second-quarter earnings. The stock is still up more than 27% so far this year. Blueprint focuses on precision medi...
-
Blueprint Medicines Reports Second Quarter 2023 Results PR Newswire -- Achieved $39.9 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 -- -- AYVAKIT approved b...
-
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023 PR Newswire CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...